发明名称 COMBINATION OF EFFECTIVE SUBSTANCES CAUSING SYNERGISTIC EFFECTS OF MULTIPLE TARGETING AND USE THEREOF
摘要 Disclosed are a combination of active components inducing synergistic effects of multi-targeting and a use thereof. More particularly, disclosed are a functional food composition, a cosmetic composition, a pain-suppressive composition, and a composition for treatment or prevention of pruritus or atopic dermatitis, which comprise as active components, two or more components selected from a group consisting of (a) a 5-hydroxytryptamine subtype 2 (5-HT2) receptor antagonist; (b) a P2X receptor antagonist; and (c) any one of a glycine receptor agonist, a glycine transporter (GlyT) antagonist, a gamma-aminobutyric acid (GABA) receptor agonist, and a GABA transporter 1 (GAT1) antagonist. The multi-targeting composite composition (specifically, natural substances composite composition) has synergistic effects, and thus a treatment using a combination of respective components may achieve increased biological effects, in which mechanisms targeted by respective components are involved. Thus, the multi-targeting composite composition may not only remarkably control pain but may also increase effects of: alleviating symptoms of skin diseases such as itching and atopic dermatitis; preventing or improving depression, refreshment, pore minimization, improving wrinkles, skin regeneration, skin health, recovery of skin condition, skin whitening, preventing or improving athlete's foot, recovery of scalp health and regeneration of scalp, promoting hair growth, preventing gray hair, and improving dental and periodontal diseases, etc.
申请公布号 US2015290181(A1) 申请公布日期 2015.10.15
申请号 US201214128616 申请日期 2012.06.28
申请人 Lee Doo Hyun;Cho Sunyoung 发明人 Lee Doo Hyun;Cho Sunyoung
分类号 A61K31/445;A61K31/505;A61K36/38;A61K36/884;A61K36/744;A61K36/69;A61K31/198;A61K36/40;A61K31/166;A61K45/06 主分类号 A61K31/445
代理机构 代理人
主权项 1. A pain-suppressive composition comprising, as active components, two or more components selected from a group consisting of (a) a 5-hydroxytryptamine subtype 2 (5-HT2) receptor antagonist; (b) a P2X receptor antagonist; and (c) any one of a glycine receptor agonist, a glycine transporter (GlyT) antagonist, a gamma-aminobutyric acid (GABA) receptor agonist, and a GABA transporter 1 (GAT1) antagonist.
地址 Seoul KR